Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with ...
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell ...
Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails ...
Researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific ...
"Results from the MonumenTAL-1 study continue to show deeper response levels and a longer duration of response in patients treated with either of the approved dose options of talquetamab, while the ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Reduced-intensity dosing of talquetamab may improve tolerability without compromising efficacy among ...
New York, NY (September 1, 2022) — Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line ...
Washington: Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback